IGSF3 and colorectal carcinoma: The limited expression of CD44v3, CD44v6, and CD44v3,v8-10 splice variants in healthy colon tissue and their apparent upregulation in CRC tissue strengthens the potential use of these biomarkers for future CRC screening.